Diclofenac for Prevention of Post-ERC Pancreatitis

• Status: Not yet recruiting
• Trial end date: 2022-03-31
• Target enrollment: 0
• Participant gender: All

Summary

The study aims at assessing the effectiveness of Diclofenac for prevention of post-ERCP pancreatitis. It will be undertaken embedded in the Swedish national register for Gallstone surgery and ERCP (GallRiks). Patients are randomised to Diclofenac prior to the ERCP or no prophylaxis. GallRiks is used to identify which patients fulfill the eligibility criteria and which patients develop pancreatitis after the ERCP.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Karolinska Institutet
• Collaborator: Uppsala University
• Treatments: Diclofenac

Criteria

Inclusion Criteria:

• Patients undergoing ERCP

Exclusion Criteria:

• Decision to perform ERCP taken intraoperatively

• Intolerance/allergy against NSAID

• Patients taking NSAID daily

• Severe cardiac fail (ASA>4)

• Kidney failure (GFR<30 ml/min)

• Coagulation disorder

• History of peptic ulcer bleeding

• History of abdominoperineal resection

• Pregnancy

• Patients who do not understand Swedish